Edit |   |
Antigenic Specificity | HLA-Aw32 & HLA-A25 (MHC I) |
Clone | [SPM418] |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG2a, kappa |
Format | unconjugated |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | Flow Cytometry (FC/FACS), Immunofluorescence (IF), Immunohistochemistry (IHC) Formalin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This MAb reacts with cells bearing HLA-A25 or HLA-Aw32 antigens. In addition, a reaction was observed with a cell of phenotype A2, Aw31; B17, Bw49. HLA-A, with HLA-B and HLA-C, belongs to major histocompatibility complex (MHC) class I antigens and expresses constitutively on all nucleated cells. HLA system comprises closely linked genes controlling highly polymorphic proteins involved in the presentation of peptides to the T-cell receptor, inhibition of NK cell cytotoxicity, and rejection of tissue allotransplantation. Specific alleles at HLA loci are associated with diseases. This MAb is specifically applicable for typing peripheral T cells for the antigens HLA-A25 and HLA-Aw32. |
Immunogen | Immunogen: Normal human peripheral blood lymphocytes of phenotype A1, Aw32, B7, B37, Cw-, Cw-, DR2, DRw10 |
Other Names | [HLA-A; HLA class 1A; MHC class I HLA-A], [HLA-B; HLA-B; AS; HLAB; Bw-47; Bw-50; SPDA1; B-4901; B-5001; HLA-Cw; HLA-B15; HLA-B39; HLA-B49; HLA-B50; HLA-B55; HLA-B59; HLA-B61; HEL-S-83; HLA-DRB1; HLA-B*45ZJ; HLA-B-3506; HLA-B-3905; HLA-B-5502; HLA-B-5602; HLAB] |
Gene, Accession # | [HLA-A], Gene ID: 3106, NCBI: NP_005505.2, UniProt: P01889 |
Catalog # | MBS438898 |
Price | $190, $340, $340 |
Order / More Info | HLA-Aw32 & HLA-A25 (MHC I) Antibody from MYBIOSOURCE INC. |
Product Specific References | Vilella R et al. Monoclonal antibody against HLA-Aw32 A25. Is HLA-Aw32 an allele with no unique antigenic determinant Hum Immunol 1983, 6(1):53-62. |